IS18 - referências médicas

Edição 18

Edição Cardiologia/ Endocrinologia A ecocardiografia como ferramenta imprescindível na avaliação de pacientes hipertensos

Editorial Presidente do Conselho: Dr. Romeu Cortes Domingues Presidente DASA: Pedro Bueno

Prezados colegas,

O

grupo DASA acredita que o futuro da saúde depende da evolução tecnológica. Por isso, ao longo de toda a nossa história, mantivemos o foco pela busca contínua do que há de mais revolucionário e moderno na área de medicina diagnóstica, sempre com o propósito de melhorar a vida e a saúde de milhares de pessoas. Rumo ao futuro e às transformações que acreditamos serem indispensáveis para o nosso crescimento no setor, decidimos renovar.

E um dos primeiros passos dessa renovação é o lançamento da nova marca DASA. Inovamos com uma identidade visual muito mais moderna e com um olhar direcionado às nossas metas e aos nossos objetivos. Centrados na promoção de conexões inteligentes para a saúde, desejamos evoluir cada vez mais. Junto à nova marca queremos viver uma era de conexões, transformando dados em cuidados com a saúde.

Guiados por esse pilar, conectamos pessoas, desenvolvemos ideias, realizamos novas pesquisas, investimos em serviços e equipamentos de ponta e disseminamos conteúdos científicos atuais aos profissionais de diversas especialidades. Por isso, renovamos também nosso influente canal de comunicação entre os médicos, a Revista Inovar.

Após seis anos difundindo conteúdos relevantes entre o corpo clínico do grupo DASA e estreitando um relacionamento que se faz imprescindível em uma empresa, apresentamos o novo projeto editorial, que reflete o novo conceito da marca e se adequa às necessidades do mercado, sem perder a qualidade que sempre esteve presente nesta ferramenta de comunicação médica.

Muito mais dinâmica, agora a Revista Inovar passa a ter periodicidade mensal e traz artigos científicos segmentados por especialidades, todos reformulados em suas apresentações.

Nesta edição, trouxemos uma série de conteúdos científicos das áreas de cardiologia e endocrinologia elaborados por médicos renomados desta companhia. O empenho dedicado a cada edição, com ênfase nas especialidades segmentadas, reflete a importância de discutirmos as novidades científicas de cada área médica, para continuarmos trilhando com pioneirismo o caminho do conhecimento científico e tecnológico.

Boa leitura!

Dr. Emerson Gasparetto Vice-Presidente Médico do grupo DASA

Conselho Editorial: Dr. Emerson Gasparetto – Vice-Presidente Médico Dr. Gustavo Aguiar Campana – Diretor Médico de Análises Clínicas Dr. Leonardo Vedolin – Diretor Médico de Imagem Dra. Mônica Freire – Diretora Médica de Análises Clínicas RJ Dr. Roberto Cury – Diretor Médico de RDI SP Marcelo Luiz Mearim – Diretor de Marketing Helaine Zanzini Cury Hohendorff – Gerente de Marketing Marco Antônio de Castro – Gerente de Produto Adriana Marçalo – Especialista de Marketing Beatriz Anselmo Ferreira dos Santos – Especialista de Marketing Shirley Carolina Costa – Analista de Marketing Participaram desta edição: Prof. Dr. Carlos Eduardo Suaide Silva Dra. Cleide de Oliveira Weingrill Sabino Prof. Dr. David Le Bihan Dr. Gianfranco Zampieri Dr. Marcio Sommer Bittencourt Dr. Renan Oliveira Vaz de Melo Dra. Rica Dodo Delmar Buchler Prof. Dr. Rodrigo Bellio de Mattos Barretto Dra. Suemi Marui Tiragem: 2.680 www.dasa.com.br Grappa Marketing Editorial Diretoria: Adriano De Luca

Juliano Guarany De Luca

Editor: Adriano De Luca (MTB: 49.539) Arte: Paula Cristina d'Andréa Redação: Suênia Cardoso Revisão: Jaqueline Kanashiro contato@grappa.com.br www.grappa.com.br Fotos: Alessandro Mendes e Sergio Zacchi Responsável técnico: Dr. Octávio Fernandes (Cremesp: 142.032)

3

EDIÇÃO 18

Consequências cardiológicas da hipertensão arterial

Referências Bibliográficas: 1.

Pena JLB. Ecocardiograma na Hipertensão Arterial Sistêmica in Silva CES – Ecocardiografia – Princípios e Aplicações Clínicas, Segunda Edição, Rio de Janeiro, Livraria e Editora Revinter, 2012.

2.

Burt VL, Ehelton P, Roccella EJ et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995;25:305-13.

3.

Linha guia de hipertensão arterial / SAS. – 2. ed. – Curitiba: SESA, 2018.

4.

Disponível em: <http://portalms.saude.gov.br/saude-de-a-z/hipertensao>.

5.

Whelton et al. High Blood Pressure Clinical Practice Guideline J Am Coll Cardiol 2018;71:e127–248.

6.

GrossmanW. Cardiac hypertrophy. Useful adaptation or pathologic process? Am J Med 1980;69:576-84.

7.

Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334-41.

8.

Levy D, Garrison RJ, Savage DD et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.NEngl J Med 1990;322:1551-66.

9.

Verdecchia P, Angeli F, Gattobigio R et al. Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects. Am J Hypert 2006;19:493-99.

10. KorenMJ, Devereux RB, Casale PN et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann InternMed 1991;114:345-52.

11. Marwick TH, Gillebert TC, Aurigemma G, et al. Am Soc Echocardiogr 2015;28:727-54.

12. Devereux RB, Savage DD, Drayer JIM. Left ventricular hypertrophy andfunction in high, normal and low renin forms of essential hypertension. Hypertension 1982;4:524-31.

13. Blake J, Devereux RB, Herrold EMet al. Relation of concentric left ventricular hypertrophy and extracardiac target organ damage to supranormal left ventricular performance in established essential hypertension. Am J Cardiol 1988;62-246-52.

MAPA: Uma rotina acima de 50 anos?

Referências Bibliográficas: 1.

Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002;360:1903-13.

2.

Rapsomaniki E, Timmis A, George J, et al. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. Lancet. 2014;383:1899-911.

EDIÇÃO 18 3.

Whelton PK,Carey RM,Aronow WS et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APha/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines J Am Coll of Cardiol 2017;24430(nov).doi.10.1016/jacc 2017.11.006

4.

Centers for Disease Control and Prevention. National Diabetes Statistics Report: Estimates of Diabetes and Its Burden in the United States. Atlanta, GA: U.S. Department of Health and Human Services; 2014.

5.

Muntner P, Carey RM,Gidding S et al. Potencial US population impact on the 2017 ACC/AHA high blood pressure guideline . J Am Coll Cardio 2018;71(2):109-118.

6.

Hemmelgarn BR, McAllister FA, Myers MG, et al. The 2005 Canadian Hypertension Education Programrecommendations for the management of hypertension: part 1- blood pressure measurement, diagnosisand assessment of risk. Can J Cardiol 2005; 21:645.

7.

Lim SS, Vos T, Flaxman AD, et al. A comparativerisk assessment of burden of disease and injuryattributable to 67 risk factors and risk factor clusters in21 regions, 1990-2010: a systematic analysis for theGlobal Burden of Disease Study 2010. Lancet. 2012;380:2224–60.

8.

Forouzanfar MH, Liu P, Roth GA, et al. Globalburden of hypertension and systolic blood pressure ofat Least 110 to 115 mm Hg, 1990-2015. JAMA. 2017;317:165–82.

9.

Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee onPrevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560

10. Pickering TG, Miller NH, Ogedegbe G, et al. Call to action on use and reimbursement for home blood pressure monitoring: executive summary: a joint scientific statement from the American Heart Association, American Society Of Hypertension, and Preventive Cardiovascular Nurses Association. Hypertension 2008; 52:1.

11. Head GA, Mihailidou AS, Duggan KA, et al. Definition of ambulatory blood pressure targets fordiagnosis and treatment of hypertension in relation to clinic blood pressure: prospective cohort study.BMJ 2010; 340:c1104 12. 6ª Diretrizes de Monitorização Ambulatorial da Pressão Arterial e 4ª Diretrizes de Monitorização Residencial da Pressão Arterial. Arq Bras Cardiol 2018; 110 (5 Supl.1):1-29 13. Nobre F, Mion Junior D. Ambulatory blood pressure monitoring: five decades of more light and less shadows.

Arq Bras Cardiol. 2016;106(6):528-37. doi: 10.5935/abc.20160065 14. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management ofhypertension in the community a statement by the American Society of Hypertension and theInternational Society of Hypertension.

J Hypertens 2014; 32:3.

15. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterialhypertension: the Task Force for the management of arterial hypertension of the European Society ofHypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31:1281.

16. Piper MA, Evans CV, Burda BU, et al. Diagnostic and predictive accuracy of blood pressure screeningmethods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med 2015; 162:192.

17. O'Brien E, Asmar R, Beilin L, et al. Practice guidelines of the European Society of Hypertension forclinic, ambulatory and self blood pressure measurement. J Hypertens 2005; 23:697.

EDIÇÃO 18

18. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105 19. Eguchi K, Hoshide S, Hoshide Y, Ishikawa S, Shimada K, Kario K. Reproducibility of ambulatory blood pressure in treated and untreated hypertensive patients. J Hypertens. 2010;28(5):918-24. doi: 10.1097/ HJH.0b013e3283378477 20. Staessen JA, Fagard RH, Lijnen PJ, et al. Mean and range of the ambulatory pressure in normotensive subjects from a meta-analysis of 23 studies. Am J Cardiol 1991; 67:723.

21. Staessen JA, Bieniaszewski L, O'Brien E, et al. Nocturnal blood pressure fall on ambulatory monitoring in a large international database. The "Ad Hoc' Working Group. Hypertension 1997; 29:30.)

22. Andersen MJ, Khawandi W, Agarwal R. Home blood pressure monitoring in CKD. Am J Kidney Dis 2005; 45:994 23. Fujii T, Uzu T, Nishimura M, et al. Circadian rhythm of natriuresis is disturbed in nondipper type of essential hypertension. Am J Kidney Dis 1999; 33:29.

24. Gatzka CD, Schobel HP, Klingbeil AU, et al. Normalization of circadian blood pressure profiles after renal transplantation. Transplantation 1995; 59:1270 25. Hansen TW, Jeppesen J, Rasmussen S, et al. Ambulatory blood pressure and mortality: a population based study. Hypertension 2005; 45:499.

26. Dolan E, Stanton A, Thijs L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 2005; 46:156 27. Clement DL, De Buyzere ML, De Bacquer DA, et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med 2003; 348:2407 28. Banegas JR, Ruilope LM, de la Sierra A, et al. Relationship between Clinic and Ambulatory Blood Pressure Measurements and Mortality. N Engl J Med 2018; 378:1509.

29. Pickering TG, Davidson K, Gerin W, Schwartz JE. Masked hypertension. Hypertension 2002; 40:795.

30. Mallion JM, Clerson P, Bobrie G, et al. Predictive factors for masked hypertension within a population of controlled hypertensives. J Hypertens 2006; 24:2365.

31. Pierdomenico SD, Cuccurullo F. Prognostic value of white-coat and masked hypertension diagnosed by ambulatory monitoring in initially untreated subjects: an updated meta analysis. Am J Hypertens 2011;24:52 32. Pogue V, Rahman M, Lipkowitz M, et al. Disparate estimates of hypertension control from ambulatory and clinic blood pressure measurements in hypertensive kidney disease. Hypertension 2009; 53:20.

33. Drawz PE, Alper AB, Anderson AH, et al. Masked Hypertension and Elevated Nighttime Blood Pressure in CKD: Prevalence and Association with Target Organ Damage. Clin J Am Soc Nephrol 2016; 11:642.

34. Fan HQ, Li Y, Thijs L, et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. Hypertens 2010; 28:2036 35. Tsivgoulis G, Vemmos KN, Zakopoulos N, et al. Association of blunted nocturnal blood pressure dip with intracerebral hemorrhage. Blood Press Monit 2005; 10:189.

36. Ingelsson E, Björklund-Bodegård K, Lind L, et al. Diurnal blood pressure pattern and risk of congestive heart failure. JAMA 2006; 295:2859 37. Lurbe E, Redon J, Kesani A, et al. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N Engl J Med 2002; 347:797.

EDIÇÃO 18

38. Vörös P, Lengyel Z, Nagy V, et al. Diurnal blood pressure variation and albuminuria in normotensive patients with insulin-dependent diabetes mellitus. Nephrol Dial Transplant 1998; 13:2257.

39. Agarwal R, Andersen MJ. Prognostic importance of ambulatory blood pressure recordings in patients with chronic kidney disease. Kidney Int 2006; 69:1175.

40. Davidson MB, Hix JK, Vidt DG, Brotman DJ. Association of impaired diurnal blood pressure variation with a subsequent decline in glomerular filtration rate. Arch Intern Med 2006; 166:846.

41. Hansen TW, Li Y, Boggia J, Thijs L, Richart T, Staessen JA. Predictive role of the nighttime blood pressure.

Hypertension. 2011;57(1):3-10. doi: 10.1161/ HYPERTENSIONAHA.109.133900 42. Niiranen TJ, Jula AM, Kantola IM, Reunanen A. Prevalence and determinants of isolated clinic hypertension in the Finnish population: the Finn-HOME study. J Hypertens 2006; 24:463.

43. Muxfeldt ES, Bloch KV, Nogueira Ada R, Salles GF. True resistant hypertension: is it possible to be recognized in the office? Am J Hypertens 2005; 18:1534.

44. Verdecchia P, Reboldi GP, Angeli F, et al. Short- and long-term incidence of stroke in white-coat hypertension.

Hypertension 2005; 45:203.

A importância da ecocardiografia no manejo do paciente valvopata

Referências Bibliográficas: 1.

Tarasoutchi F, Montera MW, Ramos AIO, Sampaio RO, Rosa VEE, Accorsi TAD et al. Atualização das Diretrizes Brasileiras de Valvopatias: Abordagem das Lesões Anatomicamente Importantes. Arq Bras Cardiol 2017; 109(6Supl.2):1-34

2.

Nishimura, R. A., C. M. Otto, R. O. Bonow, B. A. Carabello, J. P. Erwin, 3rd, L. A. Fleisher, H. Jneid, M. J. Mack, C. J. McLeod, P. T. O'Gara, V. H. Rigolin, T. M. Sundt, 3rd and A. Thompson (2017). "2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Circulation 135(25): e1159-e1195.

3.

Baumgartner, H., V. Falk, J. J. Bax, M. De Bonis, C. Hamm, P. J. Holm, B. Iung, P. Lancellotti, E. Lansac, D. Rodriguez Munoz, R. Rosenhek, J. Sjogren, P. Tornos Mas, A. Vahanian, T. Walther, O. Wendler, S. Windecker, J. L. Zamorano and E. S. C. S. D. Group (2017). "2017 ESC/EACTS Guidelines for the management of valvular heart disease." Eur Heart J 38(36): 2739-2791.

EDIÇÃO 18

Obesidade e desordens tireoidianas: Fatos e mitos Referências Bibliográficas: 1.

Cappelli C et al. 2012 Morbid obesity in women is associated to a lower prevalence of thyroid nodules. Obes Surg 22: 460–4.

2.

Celi FS et al. 2011 Metabolic effects of liothyronine therapy in hypothyroidism: a randomized, doubleblind, crossover trial of liothyronine versus levothyroxine. J Clin Endocrinol Metab 96:3466–3474.

3.

Kaptein EM et al. 2009 Thyroid hormone therapy for obesity and nonthyroidal illnesses: a systematic review. J Clin Endocrinol Metab 94:3663–3675

4.

Jonklaas J et al. 2014 Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement. Thyroid 24(12):1670-751.

Sgarbi JA et al. 2013 The Brazilian consensus for the clinical approach and treatment of subclinical hypothyroidism in adults: recommendations of the thyroid Department of the Brazilian Society of Endocrinology and Metabolism. Sgarbi JA, Teixeira PF, Maciel LM, Mazeto GM, Vaisman M, Montenegro Junior RM, Ward LS; Brazilian Society of Endocrinology and Metabolism. Arq Bras Endocrinol Metabol.

57(3):166-83.

Monitoramento da vitamina D: Novos paradigmas

Referências Bibliográficas: 1.

Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010.

2.

Cranney C, Horsely T, O’Donnell S, Weiler H, Ooi D, Atkinson S, et al. Effectiveness and safety of vitamin D. Evidence Report/Technology Assessment No. 158 prepared by the University of Ottawa Evidence-based Practice Center under Contract No. 290-02.0021. AHRQ Publication No. 07-E013. Rockville, MD: Agency for Healthcare Research and Quality, 2007.

3.

Holick MF. Vitamin D. In: Shils ME, Shike M, Ross AC, Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Disease, 10th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.

4.

Norman AW, Henry HH. Vitamin D. In: Bowman BA, Russell RM, eds. Present Knowledge in Nutrition, 9th ed.

Washington DC: ILSI Press, 2006.

5.

Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-6S.

6.

Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.

7.

Carter GD. 25-hydroxyvitamin D assays: the quest for accuracy. Clin Chem 2009;55:1300-02.

EDIÇÃO 18 8.

Hollis BW. Editorial: the determination of circulating 25-hydroxyvitamin D: no easy task. J. Clin Endocrinol Metab 2004;89:3149-3151.

9.

Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, et al. Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 2004;89:3152-57.

10. National Institute of Standards and Technology. NIST releases vitamin D standard reference material, 2009.

11. Ferreira, CSF, et al. Consensus – reference ranges of vitamin D [25(OH)D] from the Brazilian medical societies.

Brazilian Society of Clinical Pathology/Laboratory Medicine (SBPC/ML) and Brazilian Society of Endocrinology and Metabolism (SBEM). J Bras Patol Med Lab, v. 53, n. 6, p. 377-381, December 2017.

12. Holick, M F, et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: na Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, July 2011, 96(7):1911-1930.

13. Wagner CL, Greer FR; American Academy of Pediatrics Section on Breastfeeding; American Academy of Pediatrics Committee on Nutrition. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142-1152.

14. Picciano MF. Nutrient composition of human milk. Pediatr Clin North Am 2001;48:53-67.

15. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: Exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8.

16. Webb AR, Pilbeam C, Hanafin N, Holick MF. An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. Am J Clin Nutr 1990;51:1075-81.

17. Pappa HM, Bern E, Kamin D, Grand RJ. Vitamin D status in gastrointestinal and liver disease. Curr Opin Gastroenterol 2008;24:176-83.

18. Malone M. Recommended nutritional supplements for bariatric surgery patients. Ann Pharmacother 2008;42:1851-8.

19. Compher CW, Badellino KO, Boullata JI. Vitamin D and the bariatric surgical patient: a review. Obes Surg 2008;18:220-4 20. National Institutes of Health Osteoporosis and Related Bone Diseases National Research Center. Osteoporosis overview. October 2010.

21. Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 2003;78:912-9.

22. LeBoff MS, Kohlmeier L, Hurwitz S, Franklin J, Wright J, Glowacki J. Occult vitamin D deficiency in postmenopausal US women with acute hip fracture. JAMA 1999;251:1505-11.

23. Maeda S S, et al. Recomendações da Sociedade Brasileira de Endocrinologia e Metabologia (SBEM) para o diagnóstico e tratamento da hipovitaminose D. Arq Bras Endocrinol Metab. 2014; 58/7: 411-433.

24. Holick, MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. The American Journal of Clinical Nutrition, Volume 80, Issue 6, 1 December 2004, Pages 1678S–1688S. 25. Tanaka H, Abe E, Miyaura C, et al. 1,25-Dihydroxycholeciferol and human myeloid leukemia cell line (HL-60): the presence of cytosol receptor and induction of differentiation. Biochem J 1982;204:713–9.

26. Garland CF, Garland FC, Shaw EK, Comstock GW, Helsing KJ, GorhamED. Serum25-hydroxyvitamin D and coloncancer: eight-year prospective study. Lancet 1989;18:1176–78. 99.

EDIÇÃO 18

27. GarlandFC, GarlandCF, GorhamED,YoungJF. Geographicvariation in breast cancer mortality in the United States: a hypothesis involving exposure to solar radiation. Prev Med 1990;19:614–22. 100.

28. Garland C, Shekelle RB, Barrett-Connor E, Criqui MH, Rossof AH, OglesbyP. Dietary vitaminD andc alciuman drisk of colorectal cancer: a 19-year prospective study in men. Lancet 1985;1:307–9.

29. Grant WB. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002;94: 1867–75.

30. Grant WB. An ecologic study of the role of solar UV-B radiation in reducing the risk of cancer using cancer mortality data, dietary supply data and latitude for European countries. In: MF Holick, ed. Biologic effects of light 2001. Boston: Kluwer Academic Publishing, 2002: 267–6.

31. Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 1999;51: 1711–8.

32. PonsonbyA-L, McMichaelA, vanderMeiI. Ultravioletradiation and autoimmune disease: insights from epidemiological research. Toxocology 2002;181:71–8.

33. EmbryAF, SnowdonLR, ViethR. Vitamin D and seasonalf luctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;48:271–2.

34. Rostand SG. Ultraviolet light may contribute to geographic and racial blood pressure differences. Hypertension 1979;30:150–6.

35. Vander MeiI, Ponsonby A L, Dwyer T, Blizzard L, Simmons R,Taylor B V. Pastexposuretosun, skinphenotype, and risk of multiplesclerosis: case-control study. Br Med J 2003;327:316–7.

36. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003;134:128–32.

37. Isai G, Giorgino R, Adami S. Highprevalenceofhypovitaminosis Din female type 2 diabetic population. Diabetes Care 2001;24:1496–8.

38. Ishida H, Seino Y, Matsukura S. Diabetic osteopenia and circulating levels of vitamin D metabolites in type 2 (noninsulin-dependent) diabetes. Metabolism 1985;34:797–801.

39. Davies G, Welham J, Chant D, Torrey EF, McGrath J. A systematic reviewandmetaanalysisofNorthernHemisphereseasonofbirthstudies in schizophrenia. Schizophr Bull 2003;29:587–93.

40. Kendell RE, Adams W. Exposure to sunlight, vitamin D and schizophrenia. Schizophr Res 2002;54:193–8.

41. McGrath J, Selten JP, Chant D. Long-termtrendsinsunshineduration and its association with schizophrenia birth rates and age at first registration: data from Australia and the Netherlands. SchizophrRes2002; 54:199–212.

42. Rooney MR, Harnack L, Michos ED, Ogilvie RP, Sempos CT, Lutsey PL. Trends in use of high-dose vitamin D supplements exceeding 1000 or 4000 International Units Daily, 1999-2014. JAMA. 2017;317(23):2448-2450.

43. Cavalcante IGM, et al. Effect of vitamin D3 supplementation and influence of BsmIpolymorphism of the VDR gene of the inflammatory profile andoxidative stress in elderly women with vitamin D insufficiency Vitamin D3 megadose reduces inflammatory markers. Experimental Gerontology, Volume 66, June 2015, Pages 10-16.

44. Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-83.

45. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:961-8.

EDIÇÃO 18

46. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990;112:352-64.

47. de Sevaux RGL, Hoitsma AJ, Corstens FHM, Wetzels JFM. Treatment with vitamin D and calcium reduces bone loss after renal transplantation: a randomized study. J Am Soc Nephrol 2002;13:1608-14.

48. McDuffie JR, Calis KA, Booth SL, Uwaifo GI, Yanovski JA. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002;22:814-22.

49. Compston JE, Horton LW. Oral 25-hydroxyvitamin D3 in treatment of osteomalacia associated with ileal resection and cholestyramine therapy. Gastroenterology 1978;74:900-2.

50. Gough H, Goggin T, Bissessar A, Baker M, Crowley M, Callaghan N. A comparative study of the relative influence of different anticonvulsant drugs, UV exposure and diet on vitamin D and calcium metabolism in outpatients with epilepsy. Q J Med 1986;59:569-77.

51. Alharbi F M, Update in vitamin D and multiple sclerosis. Neudosciences (Ryadh).2015 Oct, 20(4): 329-335.

Prevenção da doença cardiovascular em pacientes com Diabetes mellitus

Referências Bibliográficas: 1.

Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27(5):1047-53.

2.

Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative metaanalysis of 102 prospective studies. Lancet 2010;375(9733):2215-22.

3.

Bertoluci MC, Moreira RO, Faludi A, Izar MC, Schaan BD, Valerio CM, Bertolami MC, Chacra AP, Malachias MVB, Vencio S, Saraiva JFK, Betti R, Turatti L, Fonseca FAH, Bianco HT, Sulzbach M, Bertolami A, Salles JEN, Hohl A, Trujilho F, Lima EG, Miname MH, Zanella MT, Lamounier R, Sa JR, Amodeo C, Pires AC, Santos RD. Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM). Diabetol Metab Syndr 2017;9:53.

4.

Grundy SM, Cleeman JI, Merz CN, Brewer HB, Jr., Clark LT, Hunninghake DB, Pasternak RC, Smith SC, Jr., Stone NJ. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110(2):227-39.

EDIÇÃO 18 5.

Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339(4):229-34.

6.

Bulugahapitiya U, Siyambalapitiya S, Sithole J, Idris I. Is diabetes a coronary risk equivalent? Systematic review and meta-analysis. Diabet Med 2009;26(2):142-8.

7.

Hulten E, Bittencourt MS, O'Leary D, Shah R, Ghoshhajra B, Christman MP, Montana P, Steigner M, Truong QA, Nasir K, Rybicki F, Hainer J, Brady TJ, Di Carli MF, Hoffmann U, Abbara S, Blankstein R. Cardiometabolic risk is associated with atherosclerotic burden and prognosis: results from the partners coronary computed tomography angiography registry. Diabetes Care 2014;37(2):555-64.

8.

Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robinson J, Schwartz JS, Shero ST, Smith SC, Sorlie P, Stone NJ, Wilson PWF. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines 2013.

9.

Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney M-T, Corrà U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FDR, Løchen M-L, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WMM, Binno S. 2016 European Guidelines on cardiovascular disease prevention in clinical practiceThe Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)Developed with the special contribution of the European Association for Cardiovascular Prevention &amp; Rehabilitation (EACPR). European Heart Journal 2016;37(29):2315-2381.

10. Bertoluci MC, Pimazoni-Netto A, Pires AC, Pesaro AE, Schaan BD, Caramelli B, Polanczyk CA, Junior CV, Gualandro DM, Malerbi DA, Moriguchi E, Borelli FA, Salles JE, Junior JM, Rohde LE, Canani LH, Cesar LA, Tambascia M, Zanella MT, Gus M, Scheffel RS, Dos Santos RD. Diabetes and cardiovascular disease: from evidence to clinical practice - position statement 2014 of Brazilian Diabetes Society. Diabetol Metab Syndr 2014;6:58.

11. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347(20):1557-65.

12. Kengne AP, Batty GD, Hamer M, Stamatakis E, Czernichow S. Association of C-reactive protein with cardiovascular disease mortality according to diabetes status: pooled analyses of 25,979 participants from four U.K. prospective cohort studies. Diabetes Care 2012;35(2):396-403.

13. Scirica BM, Bhatt DL, Braunwald E, Raz I, Cavender MA, Im K, Mosenzon O, Udell JA, Hirshberg B, Pollack PS, Steg PG, Jarolim P, Morrow DA. Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. JAMA Cardiol 2016;1(9):989-998.

14. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M, Jr., Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990;15(4):827-32.

15. Detrano R, Guerci AD, Carr JJ, Bild DE, Burke G, Folsom AR, Liu K, Shea S, Szklo M, Bluemke DA, O'Leary DH, Tracy R, Watson K, Wong ND, Kronmal RA. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358(13):1336-45.

EDIÇÃO 18

16. Khaleeli E, Peters SR, Bobrowsky K, Oudiz RJ, Ko JY, Budoff MJ. Diabetes and the associated incidence of subclinical atherosclerosis and coronary artery disease: Implications for management. Am Heart J 2001;141(4):637-44.

17. Kramer CK, Zinman B, Gross JL, Canani LH, Rodrigues TC, Azevedo MJ, Retnakaran R. Coronary artery calcium score prediction of all cause mortality and cardiovascular events in people with type 2 diabetes: systematic review and meta-analysis. Bmj 2013;346:f1654.

18. Young LH, Wackers FJ, Chyun DA, Davey JA, Barrett EJ, Taillefer R, Heller GV, Iskandrian AE, Wittlin SD, Filipchuk N, Ratner RE, Inzucchi SE. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. Jama 2009;301(15):1547-55.

19. Cardiovascular Disease and Risk Management: <em>Standards of Medical Care in Diabetes—2018</em>.

Diabetes Care 2018;41(Supplement 1):S86-S104.